Perpetual Ltd Buys Shares of 10,425 Illumina, Inc. (NASDAQ:ILMN)

Perpetual Ltd acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,425 shares of the life sciences company's stock, valued at approximately $827,000.

Other large investors also recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its position in Illumina by 19.1% during the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock worth $82,000 after purchasing an additional 99 shares during the period. Freedom Investment Management Inc. increased its stake in shares of Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after purchasing an additional 101 shares during the period. Personal CFO Solutions LLC lifted its position in shares of Illumina by 9.2% during the 4th quarter. Personal CFO Solutions LLC now owns 1,789 shares of the life sciences company's stock worth $239,000 after purchasing an additional 150 shares during the last quarter. GC Wealth Management RIA LLC boosted its stake in Illumina by 9.5% during the 4th quarter. GC Wealth Management RIA LLC now owns 1,783 shares of the life sciences company's stock valued at $238,000 after purchasing an additional 154 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Illumina by 16.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company's stock worth $148,000 after buying an additional 156 shares during the period. 89.42% of the stock is owned by institutional investors.

Insider Activity

In other news, CFO Ankur Dhingra purchased 6,100 shares of the business's stock in a transaction dated Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is currently owned by insiders.

Illumina Price Performance

Illumina stock traded up $0.63 on Friday, reaching $94.79. The company's stock had a trading volume of 3,837,289 shares, compared to its average volume of 2,142,698. The business's fifty day moving average price is $82.69 and its 200 day moving average price is $98.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The company has a market cap of $15.01 billion, a price-to-earnings ratio of -15.62, a PEG ratio of 1.86 and a beta of 1.32. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the company posted $0.98 earnings per share. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ILMN shares. Guggenheim dropped their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Citigroup decreased their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Barclays reiterated an "underweight" rating and issued a $85.00 price objective (up previously from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Canaccord Genuity Group boosted their price objective on Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Finally, Stephens restated an "overweight" rating and set a $105.00 price objective on shares of Illumina in a research report on Tuesday, May 20th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $127.39.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.